Biostatistics What is biostatistics?
This Technology Center is center of expertise in statistical design and analysis of biomedical research. Researchers can benefit from the state-of-the art statistical knowledge to address research questions ranging from evaluating drug effects in trials to predicting treatment response based on high-dimensional biomarkers.read more
Requests for statistical support are handled via our webform for statistical consultation, to be found here.
Non-Radboudumc requests for support
Please contact the HEV secretarial office for more information, preferably via e-mail: email@example.com
For statistical support during your internship (“wetenschappelijke stage”), please contact the HEV secretarial office, preferably via e-mail (firstname.lastname@example.org) with heading “Studentenbalie Biostatistiek”.
Services & expertise
RTC Biostatistics aims to foster a research environment in which researchers can easily and frequently consult a statistician. Such an environment boosts research quality, reinforces scientific integrity, and ensures efficient use of research means. It has three main modes of service:
- Short advice (up to 4 hours) to support research design and analyses, for publicly or internally funded research conducted by Radboudumc.
- Project based service, preferably from the research question/design up to publication stages.
- Longer term collaboration with organisations / departments covering multiple research projects.
Impact and applications
- On annual basis approximately 400 short consultancies on research projects within Radboudumc
- Impact on drug regulatory innovation, with recent publications on subgroup analyses, master protocols, estimands and standards for evaluating biosimilars
- Improved standards for animal experiments (contributing to the 3Rs)
- Full contribution to design and analyses in approximately 100 scientific publications annually
- Key member in multiple Data Monitoring Committees
- Key statistical assessor in approximately 60 scientific advices annually from the European Medicines Agency to pharmaceutical companies